Do you routinely use a bone modifying agent in patients with metastatic RCC with bone metastases receiving a TKI?

Do you routinely use bone modifying agents in RCC with skeletal mets?

• Yes, in all patients
• Only if patient has experienced a skeletal related event
• Only during treatment periods without a TKI (eg during IO/IO then stop)
• No, I avoid BMA in RCC primarily due to ONJ risk
• No, I avoid BMA in RCC primarily due to lack of representation on trials
• No, I avoid BMA in RCC for both ONJ risk and lack of trial data
• Other